Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel With or Without Nintedanib in HER2-Negative Metastatic Breast Cancer
NCT01658462Phase 2Completed
- Sponsor
- Centre Oscar Lambret
- Start
- May 2013
- Primary completion
- Dec 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of nintedanib in breast cancer, sponsored by Centre Oscar Lambret. Started May 2013; status: completed.
02
Drugs
nintedanib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01658462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01658462.